Recombinant Human FLT1 Protein, His-tagged

• Cat.No.: FLT1-372H
• Product Overview: Recombinant Human FLT1 Protein (Ser27-Ile328) with N-His tag was expressed in E. coli.

Specification

• Description: This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened, soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.
• Source: E. coli
• Species: Human
• Tag: His
• Form: Freeze-dried powder
• Molecular Mass: Predicted Molecular Mass: 37.8 kDa
  Accurate Molecular Mass: 40 kDa
• Protein length: Ser27-Ile328
• Purity: > 90%
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months.
• Storage Buffer: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
• Reconstitution: Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Gene Information

• Gene Name: FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) [ Homo sapiens (human) ]
• Official Symbol: FLT1
• Synonyms: FLT1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); FLT; vascular endothelial growth factor receptor 1; VEGFR1; FLT-1; VEGFR-1; fms-like tyrosine kinase 1; tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor
• Gene ID: 2321
• mRNA Refseq: NM_001159920
• Protein Refseq: NP_001153392
• MIM: 165070
• UniProt ID: P17948

Reviews

07/08/2019

the FLT1 protein is an excellent choice for researchers due to its high quality, reliability, and the comprehensive technical support provided by the manufacturer.

07/17/2018

The manufacturer of FLT1 protein provides excellent technical support, ensuring that researchers receive prompt assistance and guidance when encountering any challenges or difficulties.

05/27/2016

Researchers can confidently incorporate FLT1 protein into their experiments, knowing that they have access to a reliable resource that will meet their experimental needs effectively.

Q&As

How is FLT1 linked to preeclampsia in pregnancy?

Elevated levels of soluble FLT1 have been associated with preeclampsia, a pregnancy complication. Soluble FLT1 acts as a decoy receptor, reducing the bioavailability of VEGF and contributing to vascular dysfunction.

How does FLT1 contribute to retinal diseases such as diabetic retinopathy?

FLT1 has been implicated in retinal diseases like diabetic retinopathy, where abnormal blood vessel growth can lead to vision impairment. Inhibiting FLT1 may help regulate angiogenesis in such conditions.

How is FLT1 expression regulated in the human body?

FLT1 expression is regulated by various factors, including VEGF itself, as well as hypoxia and inflammation. These factors influence the balance of angiogenic signaling.

Can FLT1 be a biomarker for certain diseases?

Yes, elevated levels of soluble FLT1 have been investigated as potential biomarkers for conditions like preeclampsia, cancer, and certain cardiovascular diseases.

Can FLT1 be targeted for anti-angiogenic therapy?

Yes, targeting FLT1 is a strategy for anti-angiogenic therapy. Inhibiting FLT1 can impede blood vessel formation, limiting the blood supply to tumors and potentially slowing their growth.